Industry-Expert Theaters
Expo, #3752, #4053 and #4103

Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

Quick Links: Saturday, April 6Sunday, April 7Monday, April 8

Saturday, April 6

10:15 – 11:15 a.m.

4001. Reframing Heart Failure: Supporting Patients on the Spectrum of Care

Industry-Expert Theater 1, #3752
Sponsored by Abbott Labs

Heart Failure is a disease that has long been treated the same way - waiting for signs and symptoms to worsen to the point of needing intervention. But, it may be time to consider that those methods are no longer serving us - and more importantly, no longer serving our patients. Join us for a discussion about how we may be able to better support our Heart Failure patients with the utilization of new technology and learnings from key clinical data.

Philip Adamson, MD, FACC
Douglas Horstmanshof, MD, FACC
Melvin R. Echols, MD, FACC

4009. Turning Point in Hypertension Care: The Symplicity™ Blood Pressure Procedure

Industry-Expert Theater 2, #4053
Sponsored by Medtronic

  • Introduction
  • The current state and magnitude of HTN, the unmet need and significance of FDA approval of Symplicity Renal Denervation system
  • The Symplicity Blood Pressure Procedure and benefits
  • The Symplicity Renal Denervation System Indication for Use and Patient Selection
  • The Symplicity Care Pathway Program, Shared Decision Making and Patient Preference
  • Patient case studies and open discussion
  • Take aways and conclusion

David Kandzari, MD
Piedmont Healthcare

Tai Kobayashi, MD
University of Pennsylvania

Tiffany Randolph, MD
Cone Health

Andrew Sharp, Prof.
University Hospital of Wales

Raven Voora, MD
University of North Carolina

4017. Antiarrhythmic Drugs: Reconsider Your Approach

Industry-Expert Theater 3, #4103
Sponsored by Sanofi

12:45 – 1:45 p.m.

4002. On Target, On Track: Navigating LDL-C Management in Appropriate Patients With Primary Hyperlipidemia

Industry-Expert Theater 1, #3752
Sponsored by Novartis Pharmaceuticals Corporation

Join us for a thought-provoking discussion driven by some of the latest data in lipid management. Come and uncover insights on identifying the appropriate patient types for LDL-C lowering. Gain a deeper understanding around a treatment option for your patients with primary hyperlipidemia. Get your questions answered during our live Q&A, and obtain key information for successful integration into clinical practice.

Cheryl A. Abbas, PharmD, BCPS, FAHA
Maisha Rudison Bryant

4010. Explore the Impact of Human-centered Care in the Management of Obstructive Hypertrophic Cardiomyopathy (oHCM)

Industry-Expert Theater 2, #4053
Sponsored by Cytokinetics

During this interactive session faculty will showcase patient cases and delve into the diagnostic complexities, treatment guidelines, and the overall impact of the disease. The panel will analyze considerations occurring in oHCM management and treatment paradigms.

Martin S. Maron, MD
Matt Martinez, MD
Sara Saberi, MD, MS

4018. The HDL Hypothesis: Past, Present and Future

Industry-Expert Theater 3, #4103
Sponsored by CSL Behring

Following an AMI, the risk of recurrent CV events remains high, particularly during the first 90 days. Despite advances in standard of care treatment, an unmet therapeutic need persists for these patients. This engaging symposium brings together an expert faculty to explore the mechanism of cholesterol efflux and its impact on post-AMI CV events. The panel will outline the pivotal role ApoA-I, a key functional component of HDL, plays in this setting, and discuss recent developments in the high-risk post-AMI landscape.

C. Michael Gibson, MD
Roxana Mehran, MD
Robert Harrington, MD

3:15 – 4:15 p.m.

4003. Help Your Patients Lower Their LDL-C and Reduce Risk of Another MI or Stroke

Industry-Expert Theater 1, #3752
Sponsored by Amgen

In this presentation we will discuss a treatment option and the recommendations from the 2022 ACC Expert Consensus Decision Pathway, including the lower LDL-C threshold for very high risk ASCVD patients.


4011. Patient and Provider-focused Innovation For Optimal Experience With the LifeVest

Industry-Expert Theater 2, #4053
Sponsored by ZOLL

This program is intended to provide an overview and updates on decades of continuous innovation of the LifeVest Wearable Cardioverter Defibrillator and current state of the art for optimized patient and provider experience. Discussion will include up to date clinical evidence for SCD prevention and specific innovations in the LifeVest in the areas of alerts, alarms, patient experience, and provider resources to maximize holistic patient management.

John Rhyner, MD, FACC, FHRS
Christine Tanaka-Esposito, MD

4019. Addressing Risk of HF Rehospitalization With an Additional Guideline-Recommended Medication

Industry-Expert Theater 3, #4103
Sponsored by Merck

Discuss the increased risk of rehospitalization for HF with additional HFH and review an outcome study in high-risk patients with HFrEF.

Sunday, April 7

9:15 – 10:15 a.m.

4004. Have You Screened Your HFpEF Patients For Transthyretin Cardiac Amyloidosis? A Case Based Approach For General Cardiology

Industry-Expert Theater 1, #3752
Sponsored by Pfizer

Transthyretin Cardiac Amyloidosis (also known as ATTR-CM) is a serious, underrecognized and underdiagnosed cause of heart failure. Early recognition of clinical clues and accurate diagnosis are crucial to starting patients on the appropriate continuum of care. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing, and confirming ATTR-CM. The program will end with a review of the clinical data supporting an oral treatment option for patients with this progressive disease.

Brett W. Sperry, MD
Catherine Norton Marti, MD, MSc, FACC

4012. Finding Lp(a): Why the "Little" Things Matter

Industry-Expert Theater 2, #4053
Sponsored by Novartis US Medical Affairs

A disease state (non-CME), interactive Expert Panel presentation and discussion on lipoprotein(a). Experts will share updates in risk assessment, as well as laboratory and imaging modalities relating to elevated Lp(a) and its association with cardiovascular outcomes.

Nathan D. Wong, PhD, MPH
Leslie J. Donato, PhD
Leslee J. Shaw, PhD, FACC

4020. Title to be Announced

Industry-Expert Theater 3, #4103
Sponsored by BMS

11:15 a.m. – 12:15 p.m.

4005. Guidelines in Action: Translating Dyslipidemia Management in Patient Care

Industry-Expert Theater 1, #3752
Sponsored by Amgen

Join Dr. Kunadian, Dr. Marvel, and Dr. Baber as they navigate the intricacies of dyslipidemia management, turning clinical guidelines and recommendations into actionable strategies for enhancing patient care.

Vijay Kunadian, MBBS, MD, MRCP, FRCP, FESC, FACC
Francoise A. Marvel, MD
Usman Baber, MD, MS, FACC, FSCAI

4013. A Next Step in Cardiovascular Disease Management

Industry-Expert Theater 2, #4053
Sponsored by Esperion Therapeutics

The Session will cover the following information:

  • Atherosclerotic cardiovascular disease and lipid management
  • New clinical data and safety data
  • Unique mechanism of action for a treatment option

Manesh Patel, MD

4021. Strategy For the Long-term Treatment of Recurrent Pericarditis (RP)

Industry-Expert Theater 3, #4103
Sponsored by Kiniksa Pharmaceuticals

Please join Dr. Allan L. Klein, Dr. Paul Cremer, and Dr. Brittany Weber to discuss challenges associated with recurrent pericarditis management and considerations for a long-term treatment strategy. The session will be moderated by Dr. John F. Paolini, SVP, Chief Medical Officer at Kiniksa Pharmaceuticals.

Paul Cremer, MD
Brittany Weber, MD, PhD, FACC
John F. Paolini, MD, PhD, FACC - Chief Medical Officer, Kiniksa Pharmaceuticals

3:30 – 4:40 p.m.

4006. Agent of Change: PCI With Drug-Coated Balloons

Industry-Expert Theater 1, #3752
Sponsored by Boston Scientific

  • Leave the Right AGENT Behind: DCB Technology and Mechanism
  • MODERN PCI to Achieve Optimal DCB Treatment
  • Current State of AGENT Clinical Data
  • Panel Discussion | Q&A

Ajay Kirtane, MD
Eric Secemsky, MD
Kathleen Kearney, MD

4014. Ultrasound RDN is Here – Real-world Experience

Industry-Expert Theater 2, #4053
Sponsored by ReCor Medical

Naomi Fisher, MD
Ajay Kirtane, MD

4022. Title to be Announced

Industry-Expert Theater 3, #4103
Sponsored by iRhythm Technologies

Monday, April 8

9:45 – 10:45 a.m.

4007. Title to be Announced

Industry-Expert Theater 1, #3752
Sponsored by Alnylam Pharmaceuticals

4015. More Than Just Weight Loss: Discover the Power of a GLP-1 RA

Industry-Expert Theater 2, #4053
Sponsored by Novo Nordisk

Address obesity as a rising health problem in the US that is associated with other weight-related comorbidities and emphasize the pressing need to prioritize weight management. Evaluate the efficacy and safety data of an injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) for chronic weight management. Discuss data from selected trials that evaluated a GLP-1 RA as a chronic weight management therapy in adult patients with obesity or overweight and with a weight related comorbidity, in addition to lifestyle intervention.

Matthew Budoff, MD

4023. Reframing Transthyretin Amyloid Cardiomyopathy: A Lens on Evolving Advancements

Industry-Expert Theater 3, #4103
Sponsored by Medscape

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease in which amyloid deposits accumulate in the heart, stiffening the cardiac walls, and ultimately resulting in heart failure. ATTR-CM is often misdiagnosed, with a median survival around 2.7 years from diagnosis. This delay in accurate diagnosis results in delayed treatment. This master class will enhance your understanding of when you should suspect ATTR-CM, how to diagnose it early, the prognostic value of biomarkers, and the latest data on current and emerging treatment options to improve patient outcomes.

Daniel P Judge, MD
Sharmila Dorbala, MD, MPH
Brett Sperry, MD

12:15 – 1:15 p.m.

4008. China's Innovation Studies and Devices

Industry-Expert Theater 1, #3752
Sponsored by Asia Pacific Structural Heart Disease Club

4016. hATTR Progression: Addressing Polyneuropathy

Industry-Expert Theater 2, #4053
Sponsored by AstraZeneca

4024. Product Theater for ZepboundTM (tirzepatide) Injection

Industry-Expert Theater 3, #4103
Sponsored by Eli Lilly & Company

Join a presentation from one of your peers on the efficacy and safety of once-weekly Zepbound, and learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to pose questions to the speaker at the end of the session. Refreshments will be provided.

Please see the Important Safety Information for Zepbound, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the full Prescribing Information, and Medication Guide provided at the Product Theater.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Information current as of Feb. 26, 2024.

Industry-Expert Theater presentations are not part of ACC.24, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

American College of Cardiology

© 2023 American College of Cardiology Foundation. Visit

Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us